Quest Partners LLC Acquires Shares of 15,112 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 15,112 shares of the specialty pharmaceutical company’s stock, valued at approximately $175,000.

Other institutional investors have also recently bought and sold shares of the company. Great Point Partners LLC bought a new position in KalVista Pharmaceuticals in the 2nd quarter valued at $15,768,000. Emerald Advisers LLC grew its stake in KalVista Pharmaceuticals by 29.8% in the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after purchasing an additional 192,091 shares during the period. The Manufacturers Life Insurance Company grew its stake in KalVista Pharmaceuticals by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 3,314 shares during the period. Price T Rowe Associates Inc. MD grew its stake in KalVista Pharmaceuticals by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock valued at $263,000 after purchasing an additional 944 shares during the period. Finally, Susquehanna Fundamental Investments LLC grew its stake in KalVista Pharmaceuticals by 323.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 68,526 shares of the specialty pharmaceutical company’s stock valued at $807,000 after purchasing an additional 52,347 shares during the period.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the sale, the insider now owns 94,199 shares of the company’s stock, valued at $872,282.74. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at approximately $3,057,252. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,016 shares of company stock valued at $319,344. Corporate insiders own 10.50% of the company’s stock.

Wall Street Analyst Weigh In

KALV has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Monday, October 7th.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $10.09 on Thursday. KalVista Pharmaceuticals, Inc. has a one year low of $7.39 and a one year high of $16.88. The business’s fifty day moving average price is $10.99 and its 200-day moving average price is $11.94. The stock has a market capitalization of $436.09 million, a PE ratio of -2.83 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.04. As a group, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current fiscal year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).